QT / TQT Capabilities

Cardiac safety. De-risking strategy.

PharmaNet is a leading provider of comprehensive, high quality QT/TQT studies. Because cardiac safety issues have stopped many projects in their tracks, PharmaNet conducts investigational drug studies to assess risk, as early as possible, and assess the drug’s effect on the cardiovascular system.

QT/TQT studies are conducted at our facility, which comprises 200 beds in four distinct clinical units that can be combined to accommodate large cohorts. Supporting each study is an experienced team of medically trained staff and nurses. PharmaNet maintains close relationships with ECG core laboratories and can monitor as many as forty-nine patients simultaneously on its cardiac telemetry system; an ideal combination of technology for first-in-man studies of drug candidates with potential cardiac liability. Let PharmaNet’s experience designing the right study to meet regulatory and development requirements work for you.